This article is more than 5 years old. Information may no longer be current.
AHA Scientific Sessions to emphasize prevention, offer new data
Click Here to Manage Email Alerts
The Cardiology Today, Cardiology Today’s Intervention and Healio.com/Cardiology team will present live coverage from the American Heart Association 2013 Scientific Sessions, starting on Nov. 16.
“Within the meeting, we have an important focus on prevention,” Robert Harrington, MD, meeting chairman and chairman of the Stanford University School of Medicine, said at a press briefing.
Notably, the final day of the meeting will feature expert discussion of the four new clinical practice guidelines from the AHA and American College of Cardiology “about both the process of guideline development as well as … some of the key take-away messages,” Harrington said.
Other topics of interest include physical activity, resuscitation science and health policy, he added.
The conference will feature approximately 760 sessions, including 440 original research sessions, 20 late-breaking clinical trials and 19 clinical science special reports, according to Harrington. The 39 late-breaking trials and clinical science special reports were drawn from 100 submissions, which is a record, he said.
The following late-breaking trials are among those with results that might impact on clinical practice:
- Pre-hospital Induction of Mild Hypothermia in Out-of-Hospital Cardiac Arrest Patients, which studied whether inducing mild, controlled hypothermia out of hospital is better than in hospital.
- TTM, which compared target temperature management of 36°C vs. 33°C for out-of-hospital cardiac arrest.
- The China Rural Health Initiative: Sodium Reduction Study, which randomized villages in China to evaluate the effects of community-based sodium reduction programs on 24-hour urine sodium excretion and BP. “This may have important implications from a public health perspective,” Harrington said.
- ROSE AHF, which evaluated whether adding dopamine or nesiritide to optimal diuretic dosing relieves congestion and protects renal function in patients with acute HF.
- CTSN SMR, which was designed to answer the question of whether surgeons should repair or replace valves in patients with severe ischemic mitral regurgitation.
- TOPCAT, which studied whether spironolactone (Aldactone, Pfizer) can improve clinical outcomes in patients with HF with preserved ejection fraction.
- VISTA-16, which evaluated the potential of varespladib (Anthera Pharmaceuticals), a secretory phospholipase A2 inhibitor, to reduce CV events in patients with ACS.
- CORAL, which investigated the benefit of renal artery stenting at preventing CV and renal events in patients with atherosclerotic renal artery stenosis compared with medical therapy alone. “This is long-awaited by the interventional cardiology community,” Harrington said.
- COAG and EU-PACT, which investigated genetic-guided dosing for warfarin in patients with atrial fibrillation.
- ENGAGE AF-TIMI 48, which compared the clinical efficacy and safety of edoxaban (Daiichi Sankyo), a novel oral anticoagulant, with warfarin in patients with AF. It is the largest trial being presented at the sessions, Harrington said.
Our team will be onsite in Dallas throughout the sessions. Stay tuned to Healio.com/Cardiology for the latest news and developments, along with videos, physician perspectives and more.